OncoMatch/Clinical Trials/NCT07131514

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Is NCT07131514 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HRS-4642+AG +Adebrelimab for pancreatic cancer.

Phase 2RecruitingRuijin HospitalNCT07131514Data as of May 2026

Treatment: HRS-4642+AG +Adebrelimab — To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage RESECTABLE PANCREATIC CANCER (INCLUDING HIGH-RISK RESECTABLE), BORDERLINE RESECTABLE PANCREATIC CANCER (NCCN guidelines)

Excluded: Stage DISTANT METASTATIC

Imaging evaluation met the NCCN guidelines definition of resectable pancreatic cancer (including high-risk resectable) and borderline resectable pancreatic cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any anti-tumor therapy

Lab requirements

Blood counts

Adequate marrow and organ function

Kidney function

Adequate marrow and organ function

Liver function

Adequate marrow and organ function

Adequate marrow and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify